CytomX Announces Selection by Bristol-Myers Squibb of First Clinical Candidate Probody From Collaboration

On December 13, 2016 CytomX Therapeutics, Inc. (Nasdaq:CTMX), a biopharmaceutical company developing investigational Probody therapeutics for the treatment of cancer, reported that Bristol-Myers Squibb Company has selected a clinical candidate for its CTLA-4 Probody program under the strategic oncology collaboration established in May 2014. Achieving this milestone results in a $2 million payment to CytomX (Press release, CytomX Therapeutics, DEC 13, 2016, View Source;p=irol-newsArticle&ID=2229234 [SID1234517063]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Selecting a candidate for the CTLA-4 Probody program is a pivotal development in our partnership with CytomX Therapeutics and builds on our I.O. leadership," said Carl Decicco, Ph. D., Head of Discovery at Bristol-Myers Squibb. "We are studying the CTLA-4 Probody for its potential to deliver a next-generation anti-CTLA-4 therapy as we continue to explore transformational immuno-oncology medicines."

CTLA-4, a clinically validated inhibitory immune checkpoint protein, is the most advanced target from the companies’ collaboration, which now also includes three additional, unnamed targets in discovery.

"Advancing our CTLA-4 Probody program to clinical candidate stage with Bristol-Myers Squibb underscores the potential of the Probody platform to transform the field of immuno-oncology by delivering safer, more effective therapies," said Sean McCarthy, D.Phil., President and Chief Executive Officer of CytomX. "This partnership milestone, taken together with CytomX’s recently filed Investigational New Drug application for CX-072, a wholly owned PD-L1-directed Probody therapeutic, highlights the potential of our innovative platform to deliver a new generation of anti-cancer treatments."

About the Collaboration Agreement
Under the terms of the May 2014 agreement, CytomX granted Bristol-Myers Squibb exclusive worldwide rights to discover, develop and commercialize Probody therapeutics for up to four oncology targets. Bristol-Myers Squibb made an upfront payment of $50 million to CytomX in 2014, and is providing research funding over the course of the research term. Upon the selection of the third and fourth targets, Bristol-Myers Squibb paid CytomX selection payments. CytomX is also eligible to receive additional preclinical payments and up to $298 million in development, regulatory and sales milestone payments for each collaboration targe

Moleculin Presents Preclinical Data of Novel Inhibitor of Glycolysis at 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

On December Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), a preclinical pharmaceutical company focused on the development of anti-cancer drug candidates, many of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, reported its scientific presentation at the 28th EORTC-NCI-AACR (Free EORTC-NCI-AACR Whitepaper) Symposium on Molecular Targets and Cancer Therapeutics (Press release, Moleculin, DEC 13, 2016, View Source [SID1234517062]). Waldemar Priebe, PhD, Moleculin’s Founder, Founding Scientist, and Chair of the Scientific Advisory Board presented the Abstract on November 30th at the Symposium in Munich, Germany.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Wally Klemp, Chairman and CEO stated, "This presentation shows proof of concept data for our WP1122 portfolio, including data demonstrating increased survival of animals with human brain tumors treated with WP1122, as well as its biodistribution and pharmacokinetics. In non-optimal doses and treatment regimens, our lead inhibitor WP1122 performed equal to or better than the current market leader, cytotoxic drug temozolomide and significantly improved survival in animals treated with WP1122 in combination with temozolomide."

The following is an overview of the presentation, titled "Latentiation of 2-deoxy-D-glucose". No curative therapy exists for patients with high-grade malignant gliomas (GBMs). New approaches to the treatment of this disease are currently being evaluated with mixed results. One approach, that deserves to be therapeutically exploited, is targeting brain tumor metabolism. 2-Deoxy-D-glucose (2-DG), a known effective inhibitor of glycolysis, has been clinically tested but results did not meet expectations due to poor drug-like characteristics and inability to achieve therapeutic concentrations of 2-DG in the brain.

Dr. Waldemar Priebe stated, "We proposed to use latentiation of 2-DG to overcome this problem by chemically modifying biologically active 2-DG to form prodrugs with increased brain uptake that will be able to liberate in vivo the parent compound 2-DG in the brain. In our approach, we synthesized a series of differentially acetylated derivatives of 2-DG. Preliminary in vivo studies in mice of selected diacetates of 2-DG demonstrated >9 fold increased levels of 2-DG in the brain when compared with levels of 2-DG after administration of equimolar amount of 2-DG itself. Ultimately, our studies focused on a single compound 3,6-di-O-acetyl-2-deoxy-D-glucose (WP1122)."

Compound WP1122 was administered in vivo without toxic death up to the highest feasible dose of 3.0 g/kg intravenously and orally up to 6.0 g/kg. Significantly increased survival, comparable to or better than that of temozolomide, was observed for orally administered WP1122 in a U87 orthotopic glioma model at a dose of 1.25 g/kg. These promising results prompted continuation of preclinical toxicology evaluation of WP1122 aimed at the initiation of formal IND enabling studies. In addition, the proof of concept delivered by WP1122 has provided not only an effective approach to develop novel agents able to effectively cross the blood brain barrier but also a method to create a new class of dual function prodrugs by exploring biologically active acids.

Moleculin’s Chairman and CEO, Walter Klemp, concluded, "We are excited to present our results at this prestigious symposium. Clearly, the significantly increased survival data is key, especially as no curative therapy exists for patients with high-grade malignant gliomas today. We look forward to presenting additional data as we progress toward our clinical timeline."
For more information on the Symposium click: View Source

MacroGenics Highlights Progress at 2016 R&D Day

On December 13, 2016 MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases, reported an update on several of the Company’s product candidates and technology platforms (Press release, MacroGenics, DEC 13, 2016, View Source [SID1234517060]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"At today’s R&D Day, MacroGenics highlighted the continued progress our team is making to advance our growing portfolio of potential treatment options for patients with cancer, autoimmune disorders and infectious diseases," said Scott Koenig, M.D., Ph.D., President and CEO of MacroGenics. "Today, we reviewed our expanded strategy for pursuing a balanced approached across novel and validated targets to develop three immuno-oncology franchises centered around HER2, B7-H3 and PD-1. This approach underscores our belief that cancer patients may significantly benefit from combinatorial and multi-specific strategies that are directly addressed by our core scientific expertise in creating and developing antibody, DART and TRIDENT therapeutics. The promising updates we provided on 11 of our programs today underscore the potential of our approach."

Program Updates and Highlights:

HER2 Franchise. MacroGenics provided an update regarding its most advanced franchise targeting the human epidermal growth factor receptor 2, or HER2, led by margetuximab, its Fc-optimized monoclonal antibody:

Phase 3 Metastatic Breast Cancer Study. The pivotal SOPHIA study is evaluating the efficacy of margetuximab plus chemotherapy compared to trastuzumab plus chemotherapy in approximately 530 relapsed/refractory HER2-positive metastatic breast cancer patients. MacroGenics today confirmed that it expects to complete enrollment of this study by late 2018.
Phase 2 Gastric Cancer Combination of Margetuximab with Anti-PD-1 mAb. The Company presented initial clinical data from a Phase 1b/2 trial of margetuximab in combination with an anti-PD-1 monoclonal antibody (pembrolizumab) in advanced HER2-positive gastric and gastroesophageal junction cancer patients. Preliminary data from the dose escalation portion of the study includes patients with objective response following progression on previous lines of treatment with trastuzumab and chemotherapy.
Pre-Clinical DART Program. MacroGenics presented preliminary non-clinical data from a DART program designed to engage both HER2 and CD137 (4-1BB), a costimulatory molecule, allowing for tumor-targeted immune cell activation.
B7-H3 Franchise. MacroGenics highlighted its industry-leading franchise related to the therapeutic targeting of B7-H3, a member of the B7 family of molecules involved in immune regulation, that is broadly expressed in multiple solid tumors:

Enoblituzumab. The Company provided clinical updates on ongoing monotherapy and combination studies with enoblituzumab, an Fc-optimized monoclonal antibody. In the Phase 1 monotherapy study, the antibody continues to be well-tolerated and the most promising activity to-date has been observed in prostate, bladder and post-checkpoint melanoma patients, consistent with what has been previously reported. Combination studies of enoblituzumab with either an anti-CTLA-4 mAb (ipilimumab) or anti-PD-1 mAb (pembrolizumab) indicate a manageable safety profile to date as well as initial signs of antitumor activity.
MGD009. MacroGenics presented initial data from the ongoing Phase 1 dose escalation study of MGD009, a bispecific B7-H3 x CD3 DART molecule. Adverse events have been manageable to date and initial signs of antitumor activity have been observed in three patients with triple negative breast cancer, renal cell carcinoma and mesothelioma.
MGC018. The Company introduced MGC018, an anti-B7-H3 antibody drug conjugate (ADC) based on a duocarmycin payload with cleavable peptide linker licensed from Synthon Biopharmaceuticals. The Company plans to submit an Investigational New Drug (IND) application for MGC018 in 2018.
PD1-Directed Immuno-Oncology Franchise. MacroGenics introduced several new programs in its pipeline directed towards PD-1, which will enable both a broad set of combination opportunities across its portfolio and further differentiation from existing PD-1-based treatment options:

MGA012. The Company introduced MGA012, an anti-PD-1 monoclonal antibody that recently began a Phase 1 clinical study. With anti-PD-1 therapy becoming a mainstay of cancer treatment across multiple tumors, MacroGenics believes this molecule will be the basis for combination therapy with several of its proprietary molecules.
MGD013. MacroGenics is developing MGD013 to provide co-blockade of two immune checkpoint molecules expressed on T cells, PD-1 and LAG-3, for potential treatment of diseases spanning a range of solid tumors as well as hematological malignancies. The Company has observed synergistic immunoregulatory activity in vitro, demonstrating that co-blockade with a PD-1 x LAG-3 DART molecule exceeds the effects achieved by combining two separate antibodies against these targets. The Company is completing IND-enabling studies and plans to submit an IND for MGD013 in the first half of 2017.
PD-1 x CTLA-4 Program. MacroGenics is developing a multi-specific therapeutic to address the co-blockade of PD-1 and CTLA-4, two clinically validated co-inhibitory molecules expressed on T cells.
Update on DART Clinical Programs. Across its portfolio of clinical DART programs, the Company highlighted the promising features of its DART platform, including on-target engagement, manageable safety and preliminary evidence of biological activity. These DART programs include MGD009 and the following:

MGD006. MacroGenics presented elements of its initial clinical experience from the ongoing Phase 1 dose escalation study of MGD006, a CD123 x CD3 DART molecule, in patients with AML (acute myeloid leukemia) or MDS (myelodysplastic syndrome). Supportive care regimens have been refined to enable significant limitations in the severity of cytokine release syndrome (CRS). In addition, the Company has characterized predictable pharmacokinetic properties of MGD006 and established biological and preliminary clinical activity in AML patients. The Company is now recruiting patients with AML or MDS in the U.S. and Europe.
MGD007. MacroGenics presented its initial clinical experience from the ongoing Phase 1 dose escalation study of MGD007, a gpA33 x CD3 DART, in patients with primary and metastatic colorectal cancers. In this study, gastrointestinal and constitutional symptoms have been reversible and consistent with the known target distribution of gpA33. Translational findings to date have included dose-dependent binding to CD4+ and CD8+ T cells in patients’ peripheral blood as well as histological demonstration of MGD007 binding to tumor cells in tumor biopsy specimens.

MGD010. The Company presented data from the fully enrolled Phase 1 study of MGD010, a CD32B x CD79B DART molecule, being developed for potential treatment of autoimmune disorders. MGD010 was well tolerated in healthy subjects in the single ascending dose study. In addition, MGD010 was shown to down-modulate B-cell function at multiple levels and preliminary data indicated that MGD010 was able to inhibit antibody response to Hepatitis A vaccination, providing clinical evidence consistent with the molecule’s expected mechanism of action.

TTY Biopharm’s Anticancer Agent S-1 Received Reimbursement for Adjuvant Treatment of Locally-advanced Gastric Cancer

On December 13, 2016 TTY Biopharm’s (4105:TW) reported that anticancer agent S-1 Capsule received a Taiwan National Health Insurance (NHI) reimbursement for adjuvant chemotherapy of locally-advanced gastric cancer [stage II (excluding T1), IIIA or IIIB in TNM system], after the review from Pharmaceutical Benefit and Reimbursement Scheme Joint committee (PBRS) (Press release, TTY Biopharm, DEC 13, 2016, View Source [SID1234527287]). The validated date was December 1st, 2016. This was the second reimbursement indication after S-1 Capsule had received its first reimbursement for locally advanced un-resectable or metastatic pancreatic cancer patient since June, 2014. S-1 Capsule had been developed by Taiho Pharmaceutical Co., Ltd. of Japan and TTY Biopharm received an exclusive right to develop and market in Taiwan.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

According to Ministry of Health and Welfare’s database, around 3,600 to 3,800 new patients were diagnosed with gastric cancer annually. Gastric cancer was ranked the 7th in cancer incidence and 5th in mortality. For the early stage gastric cancer, the primary treatment was surgery; however, about 40% of patients who were diagnosed with stage II and III gastric cancer after surgery would still relapse and nearly 90% of the relapsed cases happened within 3 years. Unfortunately, for those relapsed patients, the median survival rate was less than 10%. The clinical practice recommended chemotherapy to be an adjuvant therapy. S-1 Capsule, after publication of a large-scale randomized Phase III clinical trial, was approved to be the first agent to decrease the risk of death by 33.1% and risk of relapse by 34.7% for stage II (excluding T1)-III gastric cancer patients. It was also the only oral chemotherapy agent with TFDA and NHI reimbursement label in Stage II-IIIB gastric cancer. Clinical results were first published on the New England Journal of Medicine and the final result was published on Journal of Clinical Oncology.

TTY Biopharm indicated: "Although the number of patients with gastric cancer has slowed down, the overall survival rate is lower than other Asian countries, Japan and South Korea for example. We keep not only reminding citizens to receive regular upper gastrointestinal examinations, but also educating public the benefits of adjuvant chemotherapy for lowering the risk of relapse and increasing chances of being cured." S-1 Capsule is expected to allow patients to maintain original lives. With reimbursement for gastric cancer patients, about 1,200 patients would be benefitted.

Actinium Pharmaceuticals Announces Submission of EU Orphan Designation Application for Actimab-A

On December 13, 2016 Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company"), a biopharmaceutical company developing innovative targeted therapies for cancers lacking effective treatment options, reported that the Company has submitted an application with the European Medicines Agency (EMA) seeking Orphan Designation for Actimab-A for patients newly diagnosed with acute myeloid leukemia (AML) age 60 and above who are ineligible for currently used induction therapies (Press release, Actinium Pharmaceuticals, DEC 13, 2016, View Source [SID1234517061]). Actimab-A is currently in a 53-patient, multicenter open label Phase 2 trial where it is being studied as a monotherapy in these patients who have low peripheral blast (PB) burden. In a previously completed Phase 1 trial, Actimab-A showed a 50% composite response rate at the dose level of 2.0 μCi/kg/fraction, which is the dose level being studied in the current Phase 2 trial, in patients with low PB burden.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Orphan designation brings significant benefits to the drug development process," said Sandesh Seth, Executive Chairman of Actinium Pharmaceuticals. "We are excited to have submitted this application with the EMA and we are optimistic that Actimab-A will soon have orphan designation in the EU just as it does in the U.S. If this were to occur, both of our clinical product candidates, Iomab-B and Actimab-A, would have orphan designation in the U.S. and EU, which are the largest addressable markets for our product candidates."

About EU Orphan Designation

The EMA, through its Committee for Orphan Medicinal Products (COMP), examines applications for orphan designation. To qualify for orphan designation, the prevalence of the condition must be less than 5 in 10,000, it must be life threatening or chronically debilitating and there must be no satisfactory method of treating the condition. Sponsors who obtain orphan designation receive numerous incentives including protocol assistance, a reduction or waving of fees and 10 years of market exclusivity should the therapy be approved. The process of filing and receiving the orphan medicines designation can take between eight to fourteen months in most cases. To learn more please visit EMA’s COMP website View Source

About Actimab-A

Actimab-A, Actinium’s most advanced alpha particle immunotherapy (APIT) product candidate, is currently in a 53-patient, multicenter Phase 2 trial for patients newly diagnosed with AML age 60 and above. Actimab-A is being developed as a first-line therapy and is a monotherapy that is administered via two 15-minute injections that are given 7 days apart. Actimab-A targets CD33, a protein abundantly expressed on the surface of AML cells via the monoclonal antibody, HuM195, which carries the potent cytotoxic radioisotope actinium-225 to the AML cancer calls. Actinium-225 gives off high-energy alpha particles as it decays, which kill cancer cells and as actinium-225 decays it produces a series of daughter atoms, each of which gives off its own alpha particle, increasing the chances that the cancer cell will be destroyed. Actimab-A is a second-generation therapy from the Company’s HuM195-Alpha program, which was developed at Memorial Sloan Kettering Cancer Center and has now been studied in almost 90 patients in four clinical trials. Actimab-A has been granted Orphan Drug Designation for newly diagnosed AML age 60 and above.